These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35815431)

  • 1. Multi-organs perioperative immune-related adverse events and postoperative bronchial anastomotic fistula in a patient receiving neoadjuvant immunotherapy with NSCLC.
    Xu Y; Lyu X; Qin Y; Ma D; Wang M; Shi J; Long Y; Tang B; Liu H
    Thorac Cancer; 2022 Aug; 13(16):2340-2345. PubMed ID: 35815431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of postoperative bronchopleural fistula after neoadjuvant immunochemotherapy in non-small cell lung cancer: case reports and review of the literature.
    Zhao R; Guan X; Zhang P; Liu Y; Xu Y; Sun C; Qiu S; Zhu W; Yang Z; Wang X
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):175. PubMed ID: 38573518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.
    Milman S; Kim AW; Warren WH; Liptay MJ; Miller C; Basu S; Faber LP
    Ann Thorac Surg; 2009 Sep; 88(3):945-50; discussion 950-1. PubMed ID: 19699925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
    Provencio M; Nadal E; Insa A; García-Campelo MR; Casal-Rubio J; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Pereira E; Royuela A; Casarrubios M; Salas Antón C; Parra ER; Wistuba I; Calvo V; Laza-Briviesca R; Romero A; Massuti B; Cruz-Bermúdez A
    Lancet Oncol; 2020 Nov; 21(11):1413-1422. PubMed ID: 32979984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of treatment-related adverse events and wound complications of surgical resection after neoadjuvant chemoimmunotherapy for non-small cell lung cancer.
    Li Y; Hu X; Zhang R; Wu N; Xia Q; Gu P
    Int Wound J; 2024 Mar; 21(3):e14831. PubMed ID: 38484730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
    Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
    Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Occlusion with Bronchial Covered Stent in the Management of Bronchial Stump Fistula after Right Middle and Lower Lobectomy: A Case Report and Literature Review].
    Huang M; Lu F; Li S; Pei Y; Wang L; Yang Y
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):299-304. PubMed ID: 33910279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with 
Chemotherapy in Resectable Non-small Cell Lung Cancer].
    Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC].
    Wang H; Han Y
    Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):822-832. PubMed ID: 38061884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer.
    Liu W; Zhang T; Zhang Q; Li L; Xu C
    BMC Pulm Med; 2022 Dec; 22(1):490. PubMed ID: 36582007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bronchopleural fistula in the surgery of non-small cell lung cancer: incidence, risk factors, and management.
    Sirbu H; Busch T; Aleksic I; Schreiner W; Oster O; Dalichau H
    Ann Thorac Cardiovasc Surg; 2001 Dec; 7(6):330-6. PubMed ID: 11888471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer.
    Tong BC; Gu L; Wang X; Wigle DA; Phillips JD; Harpole DH; Klapper JA; Sporn T; Ready NE; D'Amico TA
    J Thorac Cardiovasc Surg; 2022 Feb; 163(2):427-436. PubMed ID: 33985811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three years follow-up of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
    Ji W; Jiang Y; Li Y; Mao W; Teng L
    Neoplasma; 2024 Feb; 71(1):88-97. PubMed ID: 38506033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcoidosis-like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response.
    Shi Y; Li J; Chen M; Liu H; Ma D; Lin Y; Wang M; Xu Y
    Thorac Cancer; 2021 Dec; 12(24):3433-3436. PubMed ID: 34761878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer.
    Hu Y; Ren SY; Wang RY; Zeng C; Li JN; Xiao P; Wu F; Yu FL; Liu WL
    Front Oncol; 2021; 11():684070. PubMed ID: 34692476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small cell lung cancer.
    Roberts JR; Eustis C; Devore R; Carbone D; Choy H; Johnson D
    Ann Thorac Surg; 2001 Sep; 72(3):885-8. PubMed ID: 11565675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dense Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy for Stage IIB/IIIA Non-small Cell Lung Cancer - A Phase II trial.
    Mittal A; Malik PS; Kumar S; Saikia J; Chitikela S; Khurana S; Bharti S; Jain D; Pathy S; Thulkar S; Kumar R; Madan K; Mohan A
    Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):e553-e560. PubMed ID: 34340919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Robotic-assisted thoracic surgery following neoadjuvant chemoimmunotherapy in patients with stage III non-small cell lung cancer: A real-world prospective cohort study.
    Gao Y; Jiang J; Xiao D; Zhou Y; Chen Y; Yang H; Wang L; Zeng J; He B; He R; Li M; Liu Z
    Front Oncol; 2022; 12():969545. PubMed ID: 35992784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis.
    Jiang J; Wang Y; Gao Y; Sugimura H; Minervini F; Uchino J; Halmos B; Yendamuri S; Velotta JB; Li M
    Transl Lung Cancer Res; 2022 Feb; 11(2):277-294. PubMed ID: 35280319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacrificing the pulmonary arterial branch to the spared lobe is a risk factor of bronchopleural fistula in sleeve lobectomy after chemoradiotherapy.
    Toyooka S; Soh J; Shien K; Sugimoto S; Yamane M; Oto T; Date H; Miyoshi S
    Eur J Cardiothorac Surg; 2013 Mar; 43(3):568-72. PubMed ID: 22659891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.